Trial Profile
A Multicenter, Randomized, Masked, Controlled Study to Evaluate Retisert, and Intravitreal Fluocinolone Acetonide Implant, in the Treatment of Patients With Diabetic Macular Edema
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 03 Dec 2013
Price :
$35
*
At a glance
- Drugs Fluocinolone acetonide (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- 01 Aug 2011 Results published in Ophthalmology.
- 01 Aug 2011 Primary endpoint 'Visual-acuity' has been met (3059668).
- 16 Oct 2005 New trial record.